1
|
Bajrami B, Zhu H, Kwak HJ, Mondal S, Hou Q, Geng G, Karatepe K, Zhang YC, Nombela-Arrieta C, Park SY, Loison F, Sakai J, Xu Y, Silberstein LE, Luo HR. G-CSF maintains controlled neutrophil mobilization during acute inflammation by negatively regulating CXCR2 signaling. J Exp Med 2016; 213:1999-2018. [PMID: 27551153 PMCID: PMC5030805 DOI: 10.1084/jem.20160393] [Citation(s) in RCA: 65] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2016] [Accepted: 07/19/2016] [Indexed: 12/21/2022] Open
Abstract
Luo et al. report that CXCR2 ligands are responsible for rapid neutrophil mobilization during early-stage acute inflammation and that G-CSF suppresses this mobilization by negatively regulating CXCR2-mediated intracellular signaling. Cytokine-induced neutrophil mobilization from the bone marrow to circulation is a critical event in acute inflammation, but how it is accurately controlled remains poorly understood. In this study, we report that CXCR2 ligands are responsible for rapid neutrophil mobilization during early-stage acute inflammation. Nevertheless, although serum CXCR2 ligand concentrations increased during inflammation, neutrophil mobilization slowed after an initial acute fast phase, suggesting a suppression of neutrophil response to CXCR2 ligands after the acute phase. We demonstrate that granulocyte colony-stimulating factor (G-CSF), usually considered a prototypical neutrophil-mobilizing cytokine, was expressed later in the acute inflammatory response and unexpectedly impeded CXCR2-induced neutrophil mobilization by negatively regulating CXCR2-mediated intracellular signaling. Blocking G-CSF in vivo paradoxically elevated peripheral blood neutrophil counts in mice injected intraperitoneally with Escherichia coli and sequestered large numbers of neutrophils in the lungs, leading to sterile pulmonary inflammation. In a lipopolysaccharide-induced acute lung injury model, the homeostatic imbalance caused by G-CSF blockade enhanced neutrophil accumulation, edema, and inflammation in the lungs and ultimately led to significant lung damage. Thus, physiologically produced G-CSF not only acts as a neutrophil mobilizer at the relatively late stage of acute inflammation, but also prevents exaggerated neutrophil mobilization and the associated inflammation-induced tissue damage during early-phase infection and inflammation.
Collapse
Affiliation(s)
- Besnik Bajrami
- Department of Pathology, Harvard Medical School, Boston, MA 02115 Department of Lab Medicine, The Stem Cell Program, Joint Program in Transfusion Medicine, Children's Hospital Boston, Boston, MA 02115 Dana-Farber/Harvard Cancer Center, Boston, MA 02115
| | - Haiyan Zhu
- The State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Center for Stem Cell Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
| | - Hyun-Jeong Kwak
- Department of Pathology, Harvard Medical School, Boston, MA 02115 Department of Lab Medicine, The Stem Cell Program, Joint Program in Transfusion Medicine, Children's Hospital Boston, Boston, MA 02115 Dana-Farber/Harvard Cancer Center, Boston, MA 02115
| | - Subhanjan Mondal
- Department of Pathology, Harvard Medical School, Boston, MA 02115 Department of Lab Medicine, The Stem Cell Program, Joint Program in Transfusion Medicine, Children's Hospital Boston, Boston, MA 02115 Dana-Farber/Harvard Cancer Center, Boston, MA 02115
| | - Qingming Hou
- Department of Pathology, Harvard Medical School, Boston, MA 02115 Department of Lab Medicine, The Stem Cell Program, Joint Program in Transfusion Medicine, Children's Hospital Boston, Boston, MA 02115 Dana-Farber/Harvard Cancer Center, Boston, MA 02115
| | - Guangfeng Geng
- The State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Center for Stem Cell Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
| | - Kutay Karatepe
- Department of Pathology, Harvard Medical School, Boston, MA 02115 Department of Lab Medicine, The Stem Cell Program, Joint Program in Transfusion Medicine, Children's Hospital Boston, Boston, MA 02115 Dana-Farber/Harvard Cancer Center, Boston, MA 02115
| | - Yu C Zhang
- Department of Pathology, Harvard Medical School, Boston, MA 02115 Department of Lab Medicine, The Stem Cell Program, Joint Program in Transfusion Medicine, Children's Hospital Boston, Boston, MA 02115 Dana-Farber/Harvard Cancer Center, Boston, MA 02115
| | - César Nombela-Arrieta
- Department of Pathology, Harvard Medical School, Boston, MA 02115 Department of Lab Medicine, The Stem Cell Program, Joint Program in Transfusion Medicine, Children's Hospital Boston, Boston, MA 02115 Dana-Farber/Harvard Cancer Center, Boston, MA 02115 Department of Experimental Hematology, University Hospital Zurich, 8091 Zurich, Switzerland
| | - Shin-Young Park
- Department of Pathology, Harvard Medical School, Boston, MA 02115 Department of Lab Medicine, The Stem Cell Program, Joint Program in Transfusion Medicine, Children's Hospital Boston, Boston, MA 02115 Dana-Farber/Harvard Cancer Center, Boston, MA 02115
| | - Fabien Loison
- Department of Pathology, Harvard Medical School, Boston, MA 02115 Department of Lab Medicine, The Stem Cell Program, Joint Program in Transfusion Medicine, Children's Hospital Boston, Boston, MA 02115 Dana-Farber/Harvard Cancer Center, Boston, MA 02115
| | - Jiro Sakai
- Department of Pathology, Harvard Medical School, Boston, MA 02115 Department of Lab Medicine, The Stem Cell Program, Joint Program in Transfusion Medicine, Children's Hospital Boston, Boston, MA 02115 Dana-Farber/Harvard Cancer Center, Boston, MA 02115
| | - Yuanfu Xu
- The State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Center for Stem Cell Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
| | - Leslie E Silberstein
- Department of Pathology, Harvard Medical School, Boston, MA 02115 Department of Lab Medicine, The Stem Cell Program, Joint Program in Transfusion Medicine, Children's Hospital Boston, Boston, MA 02115 Dana-Farber/Harvard Cancer Center, Boston, MA 02115
| | - Hongbo R Luo
- Department of Pathology, Harvard Medical School, Boston, MA 02115 Department of Lab Medicine, The Stem Cell Program, Joint Program in Transfusion Medicine, Children's Hospital Boston, Boston, MA 02115 Dana-Farber/Harvard Cancer Center, Boston, MA 02115
| |
Collapse
|
2
|
Rose SR, Kim MO, Korbee L, Wilson KA, Ris MD, Eyal O, Sherafat-Kazemzadeh R, Bollepalli S, Harris R, Jeng MR, Williams DA, Smith FO. Oxandrolone for the treatment of bone marrow failure in Fanconi anemia. Pediatr Blood Cancer 2014; 61:11-9. [PMID: 24019220 DOI: 10.1002/pbc.24617] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2012] [Accepted: 05/03/2013] [Indexed: 12/22/2022]
Abstract
BACKGROUND A majority of Fanconi anemia (FA) patients will experience bone marrow failure (BMF) and androgen therapy (most often oxymetholone) may be utilized as a treatment to improve BMF-related cytopenias. However, oxymetholone is associated with toxicities making identification of other agents of interest. In this study we aimed to evaluate the toxicity profile and hematologic response in patients with FA who are treated with low-dose oxandrolone, a synthetic non-fluorinated anabolic steroid, similar to oxymetholone, with known dosing thresholds for virilization. PROCEDURE A single arm, Phase I/II study was designed to treat patients on low-dose oxandrolone. If no toxicity or hematologic response was noted at 16 weeks, a single dose escalation was offered. Subjects were regularly assessed for toxicity, including determinations of virilization, behavioral changes, and liver and kidney function. At 32 weeks, those who demonstrated hematologic response were allowed to continue study treatment, and those without improvement were deemed non-responsive. RESULTS Nine subjects completed the study and were followed for a median of 99 weeks (46-136 weeks). Three (33.3%) subjects developed mild sub-clinical virilization and continued treatment with a dose reduction. None (0%) had adverse behavioral changes. Two (22.2%) developed elevated liver function tests at 42 and 105 weeks. Seven (77.8%) subjects had a hematologic response. CONCLUSION Oxandrolone appears to be well-tolerated, has limited toxicities at the administered doses in FA with patients, and may be an alternative androgen for the treatment of BMF in FA.
Collapse
Affiliation(s)
- Susan R Rose
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Division of Endocrinology, Stanford University School of Medicine, Stanford, California
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|